Antibody tests for identification of current and past infection with SARS‐CoV‐2
T Fox, J Geppert, J Dinnes, K Scandrett… - Cochrane database …, 2022 - cochranelibrary.com
Background The diagnostic challenges associated with the COVID‐19 pandemic resulted in
rapid development of diagnostic test methods for detecting SARS‐CoV‐2 infection. Serology …
rapid development of diagnostic test methods for detecting SARS‐CoV‐2 infection. Serology …
Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: serologic testing
Background The role of serologic testing for SARS-CoV-2 has evolved during the pandemic
as seroprevalence in global populations has increased. The Infectious Diseases Society of …
as seroprevalence in global populations has increased. The Infectious Diseases Society of …
Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study
Background Many patients receiving dialysis in the USA share the socioeconomic
characteristics of underserved communities, and undergo routine monthly laboratory testing …
characteristics of underserved communities, and undergo routine monthly laboratory testing …
Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy
SP Gadani, M Reyes-Mantilla, L Jank, S Harris… - …, 2021 - thelancet.com
Abstract Background Sphingosine-1-phosphate receptor (S1P) modulators and anti-CD20
therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies …
therapies impair humoral responses to SARS-CoV-2 mRNA vaccines. Relatively few studies …
Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large cohort of previously infected persons
LR Petersen, S Sami, N Vuong… - Clinical Infectious …, 2021 - academic.oup.com
Background Reports suggest that some persons previously infected with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) lack detectable immunoglobulin G (IgG) …
respiratory syndrome coronavirus 2 (SARS-CoV-2) lack detectable immunoglobulin G (IgG) …
Durability of antibody levels after vaccination with mRNA SARS-CoV-2 vaccine in individuals with or without prior infection
D Zhong, S Xiao, AK Debes, ER Egbert, P Caturegli… - Jama, 2021 - jamanetwork.com
Methods| A convenience sample of 3500 health care workers from the Johns Hopkins
Health System were enrolled starting June 2020 and followed up through September 3 …
Health System were enrolled starting June 2020 and followed up through September 3 …
Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
M Li, EJ Beck, O Laeyendecker, Y Eby… - Blood …, 2022 - ashpublications.org
The ongoing evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants severely limits available effective monoclonal antibody therapies. Effective drugs …
variants severely limits available effective monoclonal antibody therapies. Effective drugs …
Risk factors associated with SARS-CoV-2 seropositivity among US health care personnel
JT Jacob, JM Baker, SK Fridkin, BA Lopman… - JAMA network …, 2021 - jamanetwork.com
Importance Risks for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection among health care personnel (HCP) are unclear. Objective To evaluate the risk …
infection among health care personnel (HCP) are unclear. Objective To evaluate the risk …
Recent advances, approaches and challenges in targeting pathways for potential COVID-19 vaccines development
During the COVID-19 pandemic in a modern era, there is a global consensus on the need
for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable …
for the rapid development of a vaccine against SARS-CoV-2 for effective and sustainable …
Association of vaccine type and prior SARS-CoV-2 infection with symptoms and antibody measurements following vaccination among health care workers
AK Debes, S Xiao, E Colantuoni, ER Egbert… - JAMA internal …, 2021 - jamanetwork.com
Methods| In June 2020, HWs in the Johns Hopkins Health System provided oral informed
consent to participate in a longitudinal study of S1 spike antibodies in which serum samples …
consent to participate in a longitudinal study of S1 spike antibodies in which serum samples …